Abiopharma

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock

SBCメディカル、普通株式3,100,000株の売出しの価格決定に関するお知らせ

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Amplitude Research Reveals a Generational AI Trust Gap is Costing Australian Businesses

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Holdings of interested parties/officers as of 31.3.26

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Sidus Space Announces Pricing of $58.5 Million Registered Direct Offering of Class A Common Stock